Longitudinal Assessment of Inflammation in Recipients of Continuous-Flow Left Ventricular Assist Devices
| Autor: | Julieta Lazarte, Arash Ghashghai, Laura C. Tumiati, Stacey Pollock Bar-Ziv, Michael McDonald, Hiroyuki Kawajiri, Vivek Rao, Liza Grosman-Rimon, Ira Jacobs, Avi Fuks, Daniel J. Shogilev, David Z.I. Cherney |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Necrosis medicine.drug_class medicine.medical_treatment Inflammation Sensitivity and Specificity Severity of Illness Index Ventricular Function Left Predictive Value of Tests Internal medicine Natriuretic Peptide Brain Natriuretic peptide medicine Humans Longitudinal Studies Macrophage inflammatory protein Chemokine CCL2 Aged Heart Failure Ejection fraction Tumor Necrosis Factor-alpha business.industry Interleukin-8 Interleukin-18 Middle Aged equipment and supplies medicine.disease Brain natriuretic peptide Surgery C-Reactive Protein Case-Control Studies Ventricular assist device Heart failure Cardiology Female Heart-Assist Devices Natriuretic Agents medicine.symptom Cardiology and Cardiovascular Medicine business Biomarkers |
| Zdroj: | Canadian Journal of Cardiology. 31:348-356 |
| ISSN: | 0828-282X |
| DOI: | 10.1016/j.cjca.2014.12.006 |
| Popis: | Background The long-term effects of continuous-flow left ventricular assist device (CF-LVAD) support on trends of inflammatory markers over time are unknown. We examined the hypothesis that the levels of inflammatory markers in CF-LVAD recipients are higher than in healthy controls and that these levels increase over time with long-term CF-LVAD support. Methods We examined the levels of inflammatory markers longitudinally at baseline before CF-LVAD implantation and at 3, 6, and 9 months after implantation. We then compared the levels of inflammatory markers to those in a healthy control group. Results Compared with baseline values before CF-LVAD implantation, left ventricular end-diastolic diameter (LVEDd) and left ventricular end-systolic diameter (LVESd) decreased significantly at 3, 6, and 9 months after CF-LVAD implantation. Brain natriuretic peptide (BNP) levels dropped significantly after CF-LVAD implantation but did not normalize. Improvements in ejection fraction at 3, 6, and 9 months after CF-LVAD implantation did not reach significance. Monocyte chemoattractant protein-1, interferon γ-induced protein, and C-reactive protein levels were higher in the CF-LVAD recipients at each of the time points (baseline before CF-LVAD implantation and 3, 6, and 9 months after implantation) compared with levels in healthy controls. In CF-LVAD recipients, serum interleukin-8, tumour necrosis factor-α, and macrophage inflammatory protein-β increased significantly at 9 months, and macrophage-derived chemokine increased at 6 months after CF-LVAD implantation compared with baseline. Conclusions Despite improvements in LV dimensions and BNP levels, markers of inflammation remained higher in CF-LVAD recipients. High levels of inflammation in CF-LVAD recipients may result from heart failure preconditioning or the long-term device support, or both. Because inflammation may be detrimental to CF-LVAD recipients, future studies should determine whether inflammatory pathways are reversible. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect